INTRODUCTION
Exposure to xenobiotics is thought to be one of the most important causes of cancer in humans. However, human genetic variability may affect the individual risk of contracting the disease. For example, among environmental carcinogens, exposure to cigarette smoke is considered one of the main causes of cancer (1, 2) , but only 15% of lifelong smokers develop a lung cancer by the age of 75 years (3) . Genetic variability governing metabolism of xenobiotics as well as DNA repair, cell cycle control, apoptosis, inflammation, and other processes are probably responsible for these inter-individual differences (4) . It is thought that the genetic factors underlying multifactorial diseases could be dissected by the use of suitable markers such as single nucleotide polymorphisms (SNPs), and by association studies comparing the differences of SNP frequencies between cases and controls. For this purpose, new methods of rapid and high-throughput genotyping analysis have been developed in the last decade (5) .
We present here an oligonucleotide microarray that allows parallel genotyping of SNPs in genes involved in xenobiotic metabolism, cell cycle control, DNA repair, and nicotine addiction (known candidates for conferring susceptibility to a broad range of diseases such as cancer) and of potential interest in pharmacogenetics. We call this microarray "MetaboChip." The MetaboChip is based on the arrayed primer extension (APEX) technology (6, 7) . APEX consists of a sequencing reaction primed by an oligonucleotide anchored with its 5′ end to a glass slide and terminating just one nucleotide before the polymorphic site. A DNA polymerase extends the oligonucleotide by adding one fluorescently labeled dideoxy nucleoside (5′) triphosphate (ddNTP) complementary to the variant base. Reading the incorporated fluorescence identifies the base in the target sequence. This method is suitable not only for SNPs but also for small insertion/deletion polymorphisms (8) .
Previously, APEX produced valuable results when 17 mutations of the β-globin and G6PD genes (7,9), 40 among the major known mutations underlying the diseases belonging to the "Finnish disease heritage" (10) , and 25 Y-chromosomal SNPs in a unique collection of samples representing five Finno-Ugric populations (11) were genotyped. It was also extensively used for resequencing 1.2 kb of the TP53 gene (12) . All these studies showed that the method is reliable, but also that each position performs differently depending on the flanking sequence, in a way that is not easily predicted in silico.
To better assess the reliability of ADH1B, ALDH2, APEX,  CDKN2A, COMT, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C9, CYP2E1, CYP3A4, DRD2, DRD4, EPHX1,  ERCC1, ERCC2, ERCC4, ERCC5, GRPR, GSTA4, GSTM3, GSTP1, GSTT2, LIG3, MDM2, MGMT, MPO, NAT1, NAT2, NQO1,  OGG1, PCNA, POLB, SLC6A3, SOD2, TP53, XRCC1, 
MATERIALS AND METHODS

DNA Samples
DNAs from the SNP500 project were kindly donated by Dr. Stephen Chanock (National Cancer Institute, Bethesda, MD, USA). The SNP500 project studies the genomes of 102 individuals of self-described heritage, culled from different geographic and ethnic populations: African, Caucasian, Hispanic, and Pacific Rim heritage. The purpose of the SNP500 project is to resequence (by direct sequencing) reference DNAs using anonymous samples from the Coriell Biorepository. The project seeks to validate known or newly discovered SNPs and other important classes of genetic variants of potential importance to molecular epidemiology studies of cancer and other diseases.
SNP Selection
We selected 93 SNPs in genes related to xenobiotic metabolism, DNA repair, cell cycle control, and nicotine addiction for which the genotypes of the reference DNAs were known by direct sequencing from the SNP500 cancer project. Because there was no special priority in doing the selection, the selected SNPs have to be considered a random sample of SNPs taken for validation purposes.
PCR Protocol
PCR amplifications of all DNA fragments containing the 93 selected polymorphisms were designed as multiplex to minimize the total number of reactions and to work under the same conditions. Briefly, multiplex PCRs were performed in a final volume of 20 µL containing 1× Platinum  Taq buffer (Invitrogen, Carlsbad, CA, USA), 1. Table 2 
APEX Protocol
Since both sense and antisense strands are sequenced, two oligonucleotides were designed for each polymorphism. The complete sequence of APEX oligonucleotides is available on the Web (http://www-gan.iarc.fr/ MetaboChip.html). 5′ (C-12) aminolinker oligonucleotides were synthesized by Sigma Genosys (Cambridge, UK) and spotted onto silanized slides as reported elsewhere (8, 14) . PCR products were pooled, purified, and concentrated using Microcon YM-30 columns (Millipore, Billerica, MA, USA). To allow better hybridization with the arrayed oligonucleotides, the PCR products were reduced in size by fragmentation. To achieve this, . Fluorescence intensities at each position were converted automatically into base calls by the software. In the case of more than one signal present on a given position, only the main signal was considered, when the intensity of the weaker signal was lower than 10% of the main signal. MICROARRAY TECHNOLOGIES discarded. Among the others, we obtained 76 SNPs (86%) with a complete concordance with genotypes reported by the SNP500 database, and 6 with a concordance of 99%. Overall, 82 out of 88 SNPs had a concordance equal to or greater than 99%. The remaining 6 had a concordance between 92% and 98.5%. The results are summarized in Table 1 .
RESULTS AND DISCUSSION
The hybridization and extension steps are conducted under the same conditions, which explains why a number of SNPs did not elicit any signal. The fact that all SNPs are processed in the same tube after pooling of PCRs is one of the advantages of the APEX approach, from the point of view of manipulation and cost. However, it also makes tuning of the conditions for individual SNPs impossible. The five failures (5/93) could be the consequence of insufficient hybridization between the oligonucleotides anchored onto the glass slide and the PCR product. Oligonucleotide design was performed by using an algorithm established for oligonucleotide in solution (NetPrimer: http: //www.premierbiosoft.com/netprimer/ netprlaunch/netprlaunch.html), to allow a theoretical hybridization at 58°C. However, it has been shown that other variables should be included in the calculation when the oligonucleotide is anchored with its 5′ end on the glass, including the electric potential of the dielectric surface and the surface conditions (15) . Moreover, secondary structures are sometimes unavoidable, because there is little freedom in choosing the position where to place the APEX oligonucleotides. Thus, we should consider the 5% failure rate as normal for this technique. Among the 88 SNPs that gave signals, the results are promising with an overall discordance rate of 0.26%. Only 6 out of 88 SNPs had a performance lower than 99% and should not be recommended for use with sensitive applications. These discrepancies may be explained by several different aspects of the technique. Often the SNP500 project used PCR primers different from those used in our laboratory. Thus, if there is an unknown polymorphism in linkage disequilibrium with the SNP under study, positioned in the region where PCR primers anneal, there could be a skewed amplification. An asymmetrical amplification of the two homologue chromosomes could lead to errors in the calls of the SNP under study, causing a misclassification of the heterozygotes as homozygotes. Alternatively, a polymorphism in linkage disequilibrium with the one of interest could reside in the region where APEX primers anneal. In this case one of the two alleles could be biased during the APEX step. We should also consider that, although we used the direct sequencing as the gold standard to test MetaboChip, this method can be affected by possible biases. These biases include skewed amplifications of the two homologues and/or an unequal incorporation of the terminators, leading to an unbalanced height of the peaks and resulting in a potential underestimation of heterozygotes when the sequences are read by the software.
However, the overall numbers of discordances are in agreement with previous studies where APEX was shown to be a genotyping technique with high specificity and sensitivity (7, 9, 12, 16) .
It is important to recognize that throughput of the APEX technology is lower than that of other approaches, such as TaqMan  (Applied Biosystems, Foster City, CA, USA) (17) or Invader  (Third Wave Technologies, Madison, WI, USA) (18) assays, in terms of number of samples processed. In practice, it is difficult to process more than a few hundred samples with the MetaboChip in a reasonable time span. On the other hand, it is important to note that the sheer cost of SNPspecific probes for TaqMan or Invader assays makes these approaches less attractive when more than a handful of SNPs are studied. APEX, however, offers the advantage that SNP-specific reagents are more than one order of magnitude less expensive than TaqMan. In this study we selected only polymorphisms of interest for our studies that were represented in the SNP500 database, to provide a rigorous validation. However, it is possible to produce APEX microarrays with several hundred SNPs using the same off-the-shelf technology we used for the present study (19) .
In summary, we screened a relatively large number of polymorphisms by APEX, representative of biochemical pathways involved in metabolism of xenobiotics and DNA repair. After the testing phase, we showed that 82 out of 88 SNPs are highly reliable. Thus, the low overall error rate combined with the low operating costs could make the MetaboChip an efficient tool for future studies of genetic epidemiology and pharmacogenetics.
